Intermediate-term graft loss after renal transplantation is associated with both donor-specific antibody and acute rejection

Transplantation

Volumn 97, Issue 5, 2014, Pages 534-540

  Devos, Jennifer M ^a   Gaber, Ahmed Osama ^a   Teeter, Larry D ^b   Graviss, Edward A ^b   Patel, Samir J ^a   Land, Geoffrey A ^b   Moore, Linda W ^a   Knight, Richard J ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

Acute rejection; Donor specific antibody; Kidney transplant

Indexed keywords

HLA ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; AFRICAN AMERICAN; ARTICLE; CONTROLLED STUDY; ETHNICITY; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DONOR; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY PANCREAS TRANSPLANTATION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTIBODIES; CASE-CONTROL STUDIES; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HISPANIC AMERICANS; HLA ANTIGENS; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREAS TRANSPLANTATION; RISK FACTORS; TIME FACTORS; TISSUE DONORS; TRANSPLANTATION;

EID: 84896287817     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000438196.30790.66     Document Type: Article

References (24)

1. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735
2. Garavoy MR, Rheinschmidt MA, Bigos M, et al. Flow cytometric analysis: A high technology crossmatch technique facilitating transplantation. Transplant Proc 1983; 15: 1939
3. Tait BD, Susal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013; 95: 19
4. Everly MJ, Everly JJ, Arend LJ, et al. Reducing De novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009; 9: 1063
5. Lee PC, Zhu L, Terasaki PI, Everly MJ. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation 2009; 88: 568
6. Sian Eng H, Bennett G, Chang SH, et al. Donor human leukocyte antigen specific antibodies predict development and define prognosis in transplant glomerulopathy. Hum Immunol 2011; 72: 386
7. Terasaki PI, Cai J. Human leukocyte antigen antibodies and chronic rejection: From association to causation. Transplantation 2008; 86: 377
8. Worthington JE, Martin S, Al-Husseini DM, et al. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 2003; 75: 1043
9. Zhang Q, Liang LW, Gjertson DW, et al. Development of posttransplant antidonor HLA antibodies is associated with acute humoral rejection and early graft dysfunction. Transplantation 2005; 79: 591
10. Cooper JE, Gralla J, Cagle L, et al. Inferior kidney allograft outcomes in patients with De novo donor-specific antibodies are due to acute rejection episodes. Transplantation 2011; 91: 1103
11. Piazza A, Poggi E, Borrelli L, et al. Impact of donor-specific antibodies on chronic rejection occurrence and graft loss in renal transplantation: Posttransplant analysis using flow cytometric techniques. Transplantation 2001; 71: 1106
12. Everly MJ, Rebellato LM, Haisch CE, et al. Incidence and impact of De novo donor-specific alloantibody in primary renal allografts. Transplantation 2013; 95: 410
13. Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibodymediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90: 68
14. Martin L, Charon-Barra C, Bocrie O, et al. Detection of plasma cells, C4d deposits and donor-specific antibodies on sequential graft biopsies of renal transplant recipients with chronic dysfunction. Transpl Immunol 2010; 22: 110
15. Ntokou IS, Iniotaki AG, Kontou EN, et al. Long-Term follow up for anti-HLA donor specific antibodies post renal transplantation: High immunogenicity of HLA class II graft molecules. Transpl Int 2011; 24: 1084
16. Wiebe C, Gibson IW, Blydt-Hanses TD, et al. Evolution and clinical pathologic correlations of De novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12: 1157
17. Willicombe M, Brookes P, Sergeant R, et al. De novo DQ donorspecific antibodies are associated with a significant risk of antibodymediated rejection and transplant glomerulopathy. Transplantation 2012; 94: 172-177
18. DeVos JM, Gaber AO, Knight RJ, et al. Donor-specific antibodies may contribute to poor graft outcome after renal transplantation. Kidney Int 2012; 82: 598-604
19. Cantarovich D, De Amicis S, Aki A. Post-Transplant donor-specific anti-HLA antibodies negatively impact pancreas transplantation outcome. Am J Transplant 2011; 11: 2737
20. Rush DN, Nickerosn, P, Gough J, et al. Beneficial effects of treatment of early subclinical rejection, a randomized study. J Am Soc Nephrol 1998; 9: 2129
21. Rush D. Controversies in nephrology protocol biopsies should be part of the routine management of kidney transplant recipients. Am J Kidney Dis 2002; 40: 1801
22. Legendre C, Thervet E, Skhiri H, et al. Histologic features of chronic allograft nephropathy revealed by protocol biopsies in kidney transplant recipients. Transplantation 1998; 65: 1506
23. Gloor M, Cohen AJ, Lager DJ, et al. Subclinical rejection in tacrolimus-Treated renal transplant patients. Transplantation 2002; 73: 1965
24. Knight RJ, Devos JM, Patel SJ, et al. Outcomes of living donor renal transplant with a negative cross-match and pre-Transplant donor-specific antibody. Transplant Proc 2013; 45: 1399